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Treatment of HIV-infected patients with highly active antiretroviral therapy (HAART) usually results in diminished viral
replication, increasing CD4+ cell counts, a reversal of most immunological disturbances, and a reduction in risk of morbidity
and mortality. However, approximately 20% of all HIV-infected patients do not achieve optimal immune reconstitution despite
suppression of viral replication. These patients are referred to as immunological nonresponders (INRs). INRs present with
severely altered immunological functions, including malfunction and diminished production of cells within lymphopoetic tissue,
perturbed frequencies of immune regulators such as regulatory T cells and Th17 cells, and increased immune activation,
immunosenescence,andapoptosis.Importantly,INRshaveanincreasedriskofmorbidityandmortalitycomparedtoHIV-infected
patients with an optimal immune reconstitution. Additional treatment to HAART that may improve immune reconstitution has
been investigated, but results thus far have proved disappointing. The reason for immunological nonresponse is incompletely
understood. This paper summarizes the known and unknown factors regarding the incomplete immune reconstitution in HIV
infection, including mechanisms, relevance for clinical care, and possible solutions.
1.Introduction
Treatment of HIV infection with highly active antiretroviral
therapy (HAART) usually results in diminished viral repli-
cation and increasing CD4+ cell counts. When HAART is
initiated, a biphasic response occurs with an initial high
increase in CD4+ cells primarily due to reduced apoptosis
and redistribution of memory CD4+ cells from lymphoid
tissue, followed by a slower on-going increase in part gen-
erated from production of na¨ ıve CD4+ cells [1, 2]. For how
long this increase proceeds is debatable, but cohort studies
suggest CD4+ cell recovery for at least 5 years of HAART as
long as the CD4+ cell count is <500cells/μL[ 3]. However,
approximately 20% of all HIV-infected individuals fail to
restore their CD4+ cell counts despite optimal treatment and
fully suppressed viral replication [2, 4, 5]. These individuals
are referred to as immunological nonresponders (INRs).
The deﬁnition of INR suﬀers from lack of consensus
impeding the comparison of ﬁndings. Most often INRs are
deﬁned as having CD4+ cell counts <200cells/μL while the
treatment duration needed for categorizing patients as INR
is variable. Furthermore, some study groups deﬁne INR
by the CD4+ cell increase in percentages, most commonly
<20% increase from baseline [6–9]. On the other hand, there
seems to be agreement that an adequate immune response
to HAART should include a CD4+ cells count >500cells/μL,
mainly because HIV-infected patients with this level of
immune restoration have a morbidity and mortality rate
approachingorcomparabletothoseofHIVnegativeindivid-
uals [10]. Patients with CD4+ cell counts <500cells/μLa r e
consequentlyclassiﬁed as inadequate responders. Inadequate
responders are a heterogeneous population since INR is
included within this group of patients. Thus, a large group
of inadequate responders, those with intermediate response
with CD4+ cells counts between 200 and 500cells/μL, are
poorly described, although they may have a morbidity and
mortality rate distinct from INR as well as from those with
adequate immune response [11]. In contrast, the increased
risk of long-term morbidity and mortality in INR is widely
accepted [11–13]. This demonstrates an obvious reason for2 Clinical and Developmental Immunology
delineating the cause of the poor immunological response
seen in INR. It also emphasizes the need for additional
treatment strategies for HAART. The scope of this paper is to
focusontheimmunologicalexplanationsforimmunological
nonresponse in patients with full virological responses,
clinical relevance, and feasible solutions.
2.ExplanationsofImmunologicalNonresponse
INR has been associated with a number of factors. Thus, it
has been shown that older age, a long duration of the HIV
infection prior to HAART, coinfection with hepatitis C, and
a low CD4 nadir predispose to immunological nonresponse
[13–17]. The CD4 nadir speciﬁcally appears to be critical for
the recovery of CD4+ cells [14, 15]. However, none of these
factors provide a full explanation for the lack of immune
reconstitution in INR. As a result of this, immunological
explanations have been proposed.
The CD4+ cell count in a given patient at any time is the
result of production, destruction, and traﬃc between blood
and lymphatic tissue. Thus, if the destruction exceeds the
production, the CD4+ cell count decreases. INR may have
alterations in the production of CD4+ cells resulting in a
r e d u c t i o no fo u t p u ta sw e l la sad e s t r u c t i o no fC D 4 +c e l l s
resulting in an increased turnover. Finally, the distribution of
cells between blood and lymphatic tissue may be diﬀerent in
INR.
3. Production of CD4+ Cells
3.1. Thymus and Naive Cells. CD4+ cells are created from
already existing CD4+ cells by proliferation, or they are
produced in the thymus. The genesis of the T-cell receptor
(TCR) takes place in the thymus only, and CD4+ cells
generated in the thymus lead to immune reconstitution with
a pool of CD4+ cells with full immunologic repertoire [1,
18]. Furthermore, HIV-infected patients with a large thymus
haveabetterimmunereconstitutionandabroaderimmuno-
logical repertoire than patients with a small thymus [19, 20].
The thymus was thought to be only active in childhood;
however it is replaced by fatty tissue with increase in age. It is
now evident that the thymus can also be active in adulthood,
particularly during circumstances with lymphopenia, as is
the case with HIV infection [21, 22]. Thymic tissue has been
visualized on computed tomography (CT) scans in HIV-
infected adults, and the size of the thymus has been shown to
bepositivelyassociatedwithnaiveCD4+cellcountsandtotal
CD4+ cell counts [19, 23, 24]. However, the performance of
CT scans is neither practical nor economically responsible in
HIV-infected patients, and often thymic function is assessed
indirectly as T-cell receptor excision circles (TRECs), as
recentthymicemigrants(RTEs),orsimplyasthenaiveCD4+
cell count. TRECs are stable circular DNA fragments that
are excised during the formation of TCR in the maturing
T cell in the thymus, and TRECs are not replicated during
cell division. Thus, the more immature CD4+ cells, the
higher the TREC content. A large thymus on CT scans has
been associated with a higher CD4+ TREC frequency in
HIV-infected patients [19]. During the maturation process,
T cells emigrate from the thymus into the periphery now
classiﬁed as RTE [25], and after further maturation RTEs are
classiﬁed as naive T cells. Thus, TRECS, RTEs and naive cells
are all reasonable indirect measurements of thymic output,
although the number of naive cells may be the result of
thymic output as well as peripheral proliferation.
Thymic output is dramatically reduced with age, and
the na¨ ıve cells are increasingly generated from prolifera-
tion (reviewed in [26]). RTEs express the surface marker
platelet endothelial cell adhesion molecule-1 (PECAM-1)
also known as CD31 [27, 28]. Proliferation leads to loss of
CD31 and a lower TREC count, and therefore na¨ ıve cells
in older individuals have decreasing proportions of CD31
and lower TREC counts [27, 28]. HIV leads to a disruption
in the number and function of na¨ ıve CD4+ cells in blood
as well as in lymphoid tissue [5, 29, 30]. After initiation
of HAART, thymic output and the total numbers of na¨ ıve
cells increase to subnormal levels, while the na¨ ıve T-cell
proliferation decreases [5, 29–31]. Even 7 years of HAART
rarely normalizes the na¨ ıve CD4+ cell counts to preinfection
levels [32]. The na¨ ıve compartment in INR seems to be even
more perturbed than in HIV-infected patients with a better
immune reconstitution. Thus, one study found no residual
thymic tissue on CT and PET scans in INR [33]. The same
study found low, though detectable, thymopoiesis assessed
as circulating RTE. In support of this, other studies have
found decreased levels of na¨ ıve T cells and T cells expressing
CD28 in INR [7, 34], suggesting an altered thymopoiesis
in INR. The assumption that peripheral proliferation is a
compensatory mechanism to altered thymopoesis in INR
is supported by the ﬁnding of increased proportions of
the peripheral proliferation marker Ki67 in INR, although
the same study found similar levels of RTE in INR versus
normal responders [35]. Similar levels of TREC in INR and
normal responders have also been reported [36]. It is not
known if a small thymus is predictive of INR. However, in
a prospective study of 30 HIV-infected individuals, thymic
CT scans were obtained to investigate the role of the thymus
in cellular restoration after initiation of HAART. Individuals
with abundant thymic tissue had higher naive CD4+ cell
counts at weeks 2–24 than individuals with minimal thymic
tissue [24]. Likewise, a large thymus has been shown to
be associated with better immune reconstitution in other
studies [23, 37].
Anotherwaytoassessfactorsinﬂuencingthecapabilityto
produce CD4+ cells is to examine the response to treatment
interruption. Thus, it has been demonstrated that a small
thymicvolumeandalowlevelofmemoryCD4+cellspredict
a faster loss of CD4+ cells during treatment interruption
[38, 39]. This supports thymopoiesis as being essential in
immune reconstitution. Interestingly, a newly published
prospective study of thymectomized children showed that
thymic tissue could be identiﬁed on magnetic resonance
imaging scans in the majority of these children later on in
life [40]. This highlights the great plasticity of the normal
immune system, and together with the aforementioned
ﬁndings it substantiates the evidence for permanent damage
on the thymic tissue in INR (Figure 1).Clinical and Developmental Immunology 3
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Figure 1: Factors inﬂuencing CD4+ cell count (LT: lymphatic tissue).
3.2. Bone Marrow and Progenitor Cells. T cells mature in the
thymus, but they originate from hematopoietic progenitor
cells (HPCs) in the bone marrow (BM). Thus, a functional
BM is crucial for thymopoiesis and possibly for immune
reconstitution.Recently,HPChasbeengivenmuchattention
in the hopes of realizing a functional cure for HIV infection,
more relevant than ever after the newly published report
of eradication of HIV by transplantation of CCR5-deﬁcient
HPC in the so-called Berlin-patient [41]. HIV inﬂuences
BM and HPC. First of all, impaired hematopoiesis in HIV
infection has been shown in a number of studies [42–
44]. Secondly, several studies have shown that a proportion
of HPCs express the HIV receptors CD4, CXCR4, and
CCR5 making them potentially susceptible to HIV infection
(reviewed in [45]). Recently, infection of HPC with HIV
was suggested [46], although it has been diﬃcult to deter-
mine if these HPCs are actually infected according to the
complexities of purifying and maintaining HPC in culture.
Also, measurements of infection may be confounded by
contaminationwithothercelltypesormaturationofHPCto
monocytes during in vitro culture. Furthermore, like T cells,
natural killer cells and B cells, including na¨ ıve B cells, seem
to be depleted during HIV infection [47]. HIV-associated
lymphopenia may therefore be explained by more upstream
elements of lymphocyte development than reduced thymic
o u t p u t .I nas t u d yo fB Mf r o m1 2I N Rc o m p a r e dt on o r m a l
responders, an altered cytokine production was found, and
a reduced growth of in vitro colonies was shown [34],
suggesting impaired hematopoiesis as a contributing factor
to poor immune reconstitution. However, studying the HPC
is limited by the poor access to BM, and since HPCs
enter the circulation [48], most studies are conducted on
circulating HPC in the peripheral blood. Circulating HPCs
have been found to decrease with disease progression and
to be associated with CD4+ cell count [49], supporting the
idea of BM and HPC as being essential in immunological
reconstitution. This is further supported by in vitro studies,
which has shown that treatment with the hematopoietic
growth factor granulocyte-colony-stimulating factor (G-
CSF) causes an increase in the numbers of circulating CD4+
cells [50]. Others have found that peripheral mononuclear
blood cells (PBMCs) from HIV-infected patients placed
on fetal thymus lobes from mice produced fewer CD4+
and CD8+ cells compared with PBMCs from uninfected
controls. Also, fewer functional precursors in the HIV-
infected patients were found [51]. This is consistent with
a loss in the capacity of HIV-infected patients to produce
functional T-cell progenitors in their peripheral blood. Thus,
in theory dysfunctional BM and HPC might contribute
to immunological nonresponse. However, so far very few
studies have validated the number or function of HPC in
patients with poor immune reconstitution.
3.3. Cytokines. Interleukin 7 (IL-7) is crucial in the T-
cell homeostasis, and the IL-7 responsiveness is determined
largely by the presence or absence of the IL-7 receptor (IL-
7R) which is present on most mature T cells [52]. Further-
more, IL-7 is a modulator of peripheral T-cell homeostasis
involved in maintaining the na¨ ıve T-cell pool by promoting
their survival and inducing proliferation without switching
na¨ ıve phenotype [53]. A negative correlation between IL-
7 and CD4+ cell count is described. Consequently, HIV-
infected patients show high levels of IL-7 and reduced levels
of IL-7R compared to healthy controls [54, 55], consistent
with the need for increased production of CD4+ cells and
a downregulation of the receptor due to high plasma levels.
A study found that a reduction of naive CD4+ cells in INR
was associated with a reduced expression of IL-7R and in
increased serum levels of IL-7 [6]. In addition, a higher
stromal production of IL-7 in INR compared to normal
responders has been observed [34, 56]. Considering IL-7 as
an inducer of CD4+ cell production, these ﬁndings are not4 Clinical and Developmental Immunology
surprising in patients with a low CD4+ cell count. However,
the interesting conclusion in relation to INR might be that
the source of the CD4+ cells is impaired in INR, not the
signals.
Like IL-7, interleukin 2 (IL-2) and interleukin 15 (IL-
15), which are part of the gamma-chain cytokine family,
are central regulators of T-cell proliferation, activation, and
diﬀerentiation as well (reviewed in [57]). In contrast to IL-7,
the production of IL-2 and IL-15 is compromised in HIV-
infected patients (reviewed in [58]a n d[ 59]). Moreover,
the production of IL-2 in blood from INR stimulated
with phytohaemagglutinin has been shown to be decreased
compared to HIV-infected patients with higher CD4+ cell
counts [7]. Thus, in theory improving the regulation of IL-
2 and IL-15 in HIV-infected patients might be beneﬁcial as
discussed later.
4.Destruction ofCD4+Cells
4.1. Immune Activation. Immune activation (IA) in the
natural history of HIV infection covers a broad spectrum of
cellular processes. Untreated HIV-infected patients display
elevated markers of activation in most cell compartments,
especially expression of the surface markers CD38 and HLA-
DR on T cells [60–64]. Also, high levels of proinﬂammatory
cytokines such as tumor necrosis factor alpha (TNFa),
interleukin 6 (IL-6), and interleukin 1b (IL-1b) have been
shown in plasma as well as in lymph nodes [65–68]. IA
usuallyreﬂectsanormalandhealthyresponseuponinfection
with any pathogen, including HIV, as an eﬀort to evade
infection. However, it is well established that IA is linked
to and predictive of disease progression, and IA has an
additive or stronger prognostic value than does CD4+ cell
count or viral load alone [60–64, 69–71]. This is highlighted
by the fact that a rare subgroup of HIV-infected patients,
elite controllers, who do not progress, and sustain normal
CD4+ cell counts and undetectable viral loads despite lack
of treatment have a lower IA than normal progressors do
[72]. Also, the natural hosts of simian immunodeﬁciency
virus (SIV), sooty mangabeys and African green monkeys,
do not show any signs of increased IA, T cell turnover, or
disease progression [73, 74] .T h u s ,I Ai sak e yf e a t u r ei nH I V
infection and disease progression, elegantly supported by the
fact that rats develop pneumocystic pneumonia solely as a
consequence of IA [75].
The reason for the strong predictive value of IA in
HIV infection is uncertain. In the setting of untreated HIV
infection, the level of IA might be determinant for how
fast the turnover of T cells is, thereby being related to
exhaustion. Indeed, it has been proposed that IA leads to
CD4+ cell depletion because it erodes the na¨ ıve T-cell pool
[76]. However, untreated and treated HIV infection are two
diﬀerent settings. IA declines when HAART is initiated,
although like most other immunological parameters, it is
not normalized [77–79]. IA is one of the best valued
immunological features in INR, and a number of studies
have shown elevated IA in INR compared to HIV-infected
patients with a better immunological recovery [6, 7, 35, 80].
Assuming INR to have a dysfunctional immune system, the
high level of IA could be a consequence of rather than a
reason for poor immune reconstitution. Lack of association
between the extent of CD4+ cell recovery and activation of
CD8+ cells beyond the ﬁrst year of successful HAART [81]
as well as the opposite has been found [78]. Either way, it
does not answer the question whether the increased IA is the
result of more upstream deﬁcits. Finally, increased IA during
primary HIV infection has been proposed to be predictive
of CD4+ cell depletion and poor response to HAART [82],
suggesting that preinfection host factors may predict poor
immune reconstitution.
Another aspect is the ﬁndings of an overweight of resid-
ual viremia detected by ultrasensitive assays in INR, which
seems to be linked to IA [83]. This might reﬂect release
o fa r c h i v e dv i r u s e sf r o mc e l l u l a rr e s e r v o i r sa n dm i g h tb ea
contributing factor to the higher levels of IA found in INR.
Also, one study reports a higher frequency of CXCR4 virus
in INR. They suggest X4 virus as players in the depletion of
na¨ ıve T cells in INR by triggering persistent IA and bystander
apoptosis viagp120-CXCR4 interactions[84],suggestingthe
coreceptor dominance to be involved in the level of immune
reconstitution. Moreover, it is acknowledged that CCR5
virus dominates early in infection, while X4 dominance
appears later on, and increased thymic destruction has been
associated with X4 viruses (reviewed in [85]).
4.2. Apoptosis and Senescence. Although the plasticity and
capacity for regeneration of the immune system is prodi-
gious, it may have boundaries. Thus, it becomes increasingly
plausible that a cell can undergo a limited number of
divisions and in the end will be trapped in growth arrest
and immunological senescence, referred to as the Hayﬂick
limit (reviewed in [86]). In the setting of HIV infection,
this becomes relevant due to the increased production and
turnover of cells. A possible way to determine the replicative
history is to measure the length of the telomeres, which
shorten by every cell division. The enzyme telomerase can
compensate for this shortening, and indeed HIV-infected
patientshavebeenfoundtohaveshortertelomerelengthand
dysregulated telomerase activity [87–89]. Short telomeres
can lead to chromosome instability, involving growth arrest
and apoptosis. Thus, not surprisingly HIV-infected patients
p r e s e n tw i t he l e v a t e dl e v e l so fa p o p t o s i s[ 90], and both
early and late apoptotic CD4+ cells are more prevalent in
patients with CD4+ cell counts <500cells/μL[ 90–94]. The
relevance of markers of immune exhaustion and senescence
in relation to immune reconstitution is conﬁrmed by the
ﬁndings of the expression of the activation associated T-
cell molecule programmed death-1 (PD-1). PD-1 conveys
inhibitory signals to T cells (reviewed in [95]), and PD-1 is
selectively upregulated by exhausted T cells during chronic
viralinfection[96].ElevatedlevelsofPD-1inINR compared
to normal responders have been reported [80, 97]. Also, PD-
1 expression has been shown to be negatively correlated to
CD4+cellcount,andPD-1expressingTcellsaremoreprone
to programmed cell death ligand-mediated inhibition of T
cell proliferation [97].
Finally, chronic infection with cytomegalovirus (CMV)
has been associated with immunological senescence, andClinical and Developmental Immunology 5
a high proportion of T cells speciﬁc for CMV and CMV-
viremia is associated with a low CD4+ cell count and
increased mortality ([98], reviewed in [99]).
4.3. Pro- and Anti-Inﬂammatory T Cells. During recent
years, the understanding of immune responses has changed
tremendously by the discovery of T-cell subsets with pro-
and anti-inﬂammatory properties. Th17 cells are T cells with
proinﬂammatory properties, while regulatory T cells (Tregs)
are anti-inﬂammatory. Tregs play a crucial role in sustaining
tolerance to self-antigens [100, 101] and suppressing T-
cell activation resulting in downregulation of immune
activation,including reductioninantitumorimmunity, graft
rejection, and graft-versus-host disease ([102], reviewed in
[103]). Finally, the role of Tregs in chronic viral infections,
including HIV, has gained massive interest due to their
immunosuppressive capabilities. Tregs themselves are CD4+
cells and susceptible to HIV infection [104]. Therefore, the
absolute number of Tregs declines with disease progression,
while the frequency of Tregs tends to increase and remains
high on HAART [105–108]. Thus, in a prospective study
Tregs were measured in 26 HIV-infected patients before and
after HAART and compared to healthy controls. The level
of Tregs was found to be elevated in patients compared to
controls, and this level did not change despite 6 months of
HAART [106]. Tregs are believed to be able to downregulate
chronic immune activation in HIV infection making Tregs a
key element in the understanding of the interaction between
the host immune system and HIV (reviewed in [109]).
However, Tregs might be beneﬁcial as downregulators of
the unbeneﬁcial immune activation or, in contrast, they
might have a harmful eﬀect downregulating HIV-speciﬁc
responses. So far, it is not clear whether Tregs accelerate or
delay HIV infection.
IL-17-producing Th17 cells are closely related to Tregs.
Th17 cells and Tregs share a reciprocal maturation pathway
and function together in opposing ways to control the
inﬂammatory response to infection. While Tregs inhibit
autoimmunity, Th17 cells play a role in the induction of
autoimmune tissue injury [110]. During acute SIV infection
the rapid depletion of Th17 cells and a disturbed balance
of Th17 cells and Tregs are associated with subsequent high
IA and disease progression [111]. Likewise, in HIV-infection
the loss of balance between Th17 cells/Tregs may play a part
in inducing microbial translocation and chronic immune
activation [112]( r e v i e w e di n[ 113] ) .T h ei m p o r t a n c eo f
a well-regulated balance between Tregs and Th17 cells is
demonstrated by a maintained balance between Tregs and
Th17 cells in HIV controllers [114]( r e v i e w e di n[ 115]).
Finally, recent data from our own lab show disturbances
in the Treg- and Th17 cell compartments as well as in the
balance between them in INR, suggesting an impact on im-
mune reconstitution [116].
4.4. Secondary Lymphatic Tissue. CD4+ cell depletion occurs
in the blood as well as in the secondary lymphatic tissue
(SLT) of lymph nodes (LNs) and gut-associated lymphatic
tissue (GALT) where the majority of the CD4+ cells reside.
A vast number of cells are lost during primary infection, and
by the time the infection has reached a chronic stage; more
than 50% of the CD4+ cells in the LN are lost [117, 118].
With a possible damage of primary lymphatic tissue (LT)
(i.e., thymic tissue and bone marrow) in mind, it seems
reasonable to consider damages to SLT as a consequence of
HIV infection as well, suggesting this early massive depletion
as a determinant for the level of immune reconstitution
following HAART. Thus, it has been proposed that HIV
damages the structures in the lymphatic tissue that help
sustain the normal CD4+ cell population, replacing the
functional space with collagen. It was found that the greater
the amount of the collagen-deposition, the lower the CD4+
cell count, and the smaller the number of naive CD4+ cells
[119]. Furthermore, the amount of the collagen-deposition
in LN has proven to be predictive for the degree of the
immune reconstitution [120]. Also, LN biopsies from HIV
and SIV-infected individuals show breakdown of the lymph
node architecture and evidence of apoptosis [121].
These ﬁndings are consistent with HIV as a causative
agent in damage to SLT. In light of this, it is worth noticing
that SLT serves as viral reservoirs, including a pool of latently
infected, resting CD4+ cells, which is believed to be a major
impediment to the eradication of HIV [122]. While HAART
rapidly reduces viral load in the blood, viral production
is still detectable in SLT [123, 124], and it would be
interesting to ascertain whether the pool of latently infected
cells inﬂuences immune reconstitution. So far, it has been
shown that the level of immune reconstitution is associated
with certain types of cellular reservoirs. Thus, proviral DNA
primarily persists in central memory cells in patients with a
good immune reconstitution, while patients with a poorer
reconstitution mainly host HIV proviral DNA in transitional
memory cells [125]. This suggests that the viral reservoir
inﬂuences immune reconstitution, and therefore it seems
of interest to identify treatment strategies in addition to
HAART with the ability to suppress the viral production in
SLT,possiblyleadingtolimiteddestructionofLTandabetter
immune reconstitution.
AnotheraspectisthefactthatinfectionwithHIVleadsto
redistribution of CD4+ cells between blood and lymphatic
tissue. Thus, it has been demonstrated that HIV binds to
resting CD4+ cells and upregulates L-selectin causing the
cells to home from the blood into LN at enhanced rates
[126, 127]. This has lead to the homing theory, which oﬀers
an explanation for the loss of CD4+ cells due to cells leaving
the blood and entering the LT (reviewed in [128]). Thus,
it would be interesting to evaluate the amount of CD4+
cells outside the blood in SLT in INR, which may reveal
accumulation of CD4+ cells. Indeed accumulation of Tregs
has been found in SLT compared to peripheral blood in
untreated HIV-infected patients [129].
5. ClinicalImplications:
Relevance for ClinicalCare
Treatment with HAART reduces the risk for development
of AIDS and death. Consequently, a relative increase in
morbidity and mortality has been described. Despite eﬃ-
cient treatment with HAART and suppression of viral6 Clinical and Developmental Immunology
replication, HIV-infected individuals have increased risk
of morbidity and mortality when compared to uninfected
population controls [130]. The reason for this is multi-
factorial. Thus, HIV itself is the leading cause (reviewed
in [131]). However, HAART has been shown to cause
metabolic and atherosclerotic changes (reviewed in [132,
133]).Furthermore,lifestyle-relatedfactorssuchasincreased
alcohol consumption, smoking, drug-abuse, and poverty are
all associated with being HIV infected (reviewed in [134–
137]). Finally, among HIV-infected patients coinfection with
hepatitisBandCismorecommonbecausehepatitisandHIV
share transmission routes.
However, there are great diﬀerences in the risk of mor-
bidity and mortality among diﬀerent groups of HIV infected
patients. Higher risk of opportunistic diseases and death was
discovered to be associated with relative immunodeﬁciency
in the SMART study [138], and INRs in particular have
increased risk of opportunistic infections and long-term
morbidity and mortality [11–13, 139]. Thus, INRs have
a much higher risk of opportunistic diseases and death.
In the UK CHIC study, the number of deaths/100 person
years of follow-up was a hundred times higher in the
group of patients with CD4+ cell counts below 50cells/μL
compared to CD4+ cell counts above 500cells/μL[ 140].
Contrary, HIV-infected patients without risk factors and
optimal response to HAART seem to have a mortality
comparable to HIV negative individuals [141]. Importantly,
rates of death increase substantially with declining CD4+ cell
counts at baseline along with the extent of immunological
deﬁciency prior to the period of sustained suppression
of viral replication [11–13, 142]. For this reason, patients
diagnosed with HIV in an advanced state of the disease (HIV
late-presenters) are in higher risk of being INR (reviewed in
[143]). Also, the lower the CD4 nadir, the shorter it takes for
the CD4+ cell count to drop during treatment interruption
[144].
Non-AIDS morbidity comprises of diseases such as car-
diovascular disease (CVD), cancer, renal disease, hepatic
disease, and osteoporosis. Thus, HIV-infected patients suﬀer
more from clinical as well as subclinical atherosclerotic
disease compared to the general population, and atheroscle-
rotic (CVD) is a leading cause of death in HIV-infected
patients [145]. HIV infection is associated with immune
activation and inﬂammation. Inﬂammation in turn may
lead to vascular damage and dysfunction increasing the risk
of CVD (reviewed in [146]). Furthermore, HAART may
increase the risk of myocardial infarction [147]. Either way,
a consistent relation between low CD4+ cell counts and
increased risk of CVD morbidity and mortality has been
shown in a number of studies (reviewed in [148]). Thus,
in a cross-sectional study of 1331 HIV-infected women and
600 HIV-infected men, the subclinical carotid artery lesions
and common carotid artery intima-media thickness were
measured by ultrasound. A low CD4+ cell count was found
to be independently associated with an increased prevalence
of carotid lesions [149]. The reason for this increased risk
in INR is unknown, but the increased inﬂammation seen
in patients with poor immune reconstitution as previously
described seems like a more plausible reason than does the
CD4+ cell count itself.
Likewise, HIV-infected patients have increased risk of
cancer compared to the general population. It is well known
that initially low and decreasing CD4+ cell counts during
the year prior to cancer diagnosis are predictive of AIDS-
deﬁning malignancies (ADMs) such as Kaposi sarcoma and
non-Hodgkin lymphoma as shown in the CASCADE study
[150]. Also, the COHERE study showed that during HAART
higher CD4+ cell counts are protective for the development
of non-Hodgkin lymphoma [151]. Furthermore, non-AIDS-
deﬁning malignancies (non-ADM) such as anal cancer are
more common in immune compromised patients (reviewed
in [152]). In the D:A:D study the relationship between
deaths due to ADM and non-ADM was determined, and
immunodeﬁciency was evaluated. In a large observational
cohort study including 23, 437 patients that were followed
prospectively, a low CD4+ cell count was found to be
predictive of death from both ADM and non-ADM in
HIV-infected patients [153]. Likewise, a low current CD4+
cell count was shown to be associated with an increased
incidence of certain non-ADM by the EuroSIDA group
[154]. In conclusion, as expected ADMs are closely related
to the CD4+ cell count. However, non-ADMs are related
to the CD4+ cell count as well, presumably due to a poor
immune function, especially since one study found that
48.3%ofallnon-ADMswerevirusrelated[154].Alltogether
HIV-infected patients have increased risk of developing
malignancies, and more so in the group of INR.
Finally, the HIV-associated neurocognitive disorders
(HANDs) have become an area of increasing interest as
HIV infected patients become older and live longer. In the
CHARTER study, a cross-sectional, observational study of
1,555 HIV-infected patients on HAART, the frequency and
associated features of HAND were determined. Fifty-two
percent of the total sample had neuropsychological impair-
ment with higher rates in groups with greater comorbidity
burden. The lowest impairment rate occurred in patients
with a CD4 nadir and a current CD4+ cell count above
200cells/μL[ 155]. In general, a history of a low CD4 nadir
seems be one of the strongest predictors of impairment [155,
156]. Future studies should identify whether early disease
events (e.g., profound CD4 decline) may trigger chronic
CNSchanges,andwhetherearlyHAARTpreventsorreverses
these changes.
In summary,thereremainsno doubt thata fullimmuno-
logical recovery is essential in order to reduce morbidity and
mortality among HIV-infected patients. However, obtaining
this goal requires improving earlier diagnosis and additional
treatment to HAART. Several supplementary immune-based
therapies to enhance immune reconstitution are under
investigation using cytokines, hormones, andgrowthfactors.
6. Therapeutical Possibilities
6.1. Optimizing HAART. Optimizing HAART may be a
possibility to increase CD4+ cell counts in HIV-infected
INR (systematically reviewed in [157]), and recent data on
new drug modalities such as CCR5-antagonists, integraseClinical and Developmental Immunology 7
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Figure 2: Therapeutical possibilities improving immune reconstitution. KGF: keratinocyte growth factor; IL: interleukin; GH: growth
hormone; HCV/CMV: treatment of hepatitis C virus and cytomegalovirus; Cox2i: cyclooxygenase inhibitor; TNF: tumor necrosis factor;
IVIG: intravenous immunoglobulin.
inhibitors, and fusion inhibitors increase the relevance of
this matter. HIV uses CCR5 as a coreceptor for cell entry,
which has led to development of several CCR5-antagonists
to impede HIV infection. Currently, only Maraviroc is FDA-
approved for treatment of HIV infection. The phase III
randomized clinical MOTIVATION study demonstrated that
addition of Maraviroc to HAART in pretreated patients
resulted in a signiﬁcant increase in CD4+ cell counts as well
as reduced viral load [158]. Furthermore, administration of
Maraviroc seems to result in decreased immune activation
[159]. Underlining these ﬁndings, a meta-analysis of phase
II/III clinical trials testing CCR5-antagonist in treatment-
experienced HIV patients demonstrated signiﬁcant increase
in CD4+ cell counts by adding CCR5-antagonist [160],
clearly suggesting a potential of drugs targeting CCR5
for optimizing immune reconstitution in INR. Raltegravir
targets the HIV integrase, which facilitates the integration of
the genetic material into the hosts DNA, and is at present
the only FDA-approved integrase inhibitor. The potential
of raltegravir has proven eﬀective in the large phase III
BENCHMRK study [161] showing increased CD4+ cell
counts and reduced viral loads. However, two randomized
clinical studies testing the eﬀect of raltegravir in INR did not
demonstrate an additional eﬀect on immune reconstitution
[162, 163]. Several clinical trials testing other integrase
inhibitors are ongoing (http://www.clinicaltrials.org/), and a
large phase III study comparing intensiﬁcation of HAART
with raltegravir and elvitegravir in treatment-experienced
patients demonstrated no signiﬁcant diﬀerence between
the two drugs in regard with immune reconstitution
[164]. Finally, enfuvirtide is the only FDA-approved fusion
inhibitor. It impedes fusion of HIV to the target cell by
binding to gp41. Two multicenter phase III studies (TORO
1/2) documented an eﬀect of enfuvirtide in combination
with HAART in treatment-experienced patients on both
CD4+ cell count and viral load [165, 166]. However, a large
randomized multicenter study (ANRS130) demonstrated no
additional eﬀect of supplementary enfuvirtide to HAART on
CD4+cellcountsintreatment-naivelate-presenterswithlow
CD4+ cell count [167]. Thus, at present Maraviroc seems
to be the most promising drug for HAART intensiﬁcation.
However, larger prospective studies assessing the eﬀect in
INR are needed to estimate the clinical beneﬁts of HAART
intensiﬁcation (Figure 2).
6.2. Interleukin-2 (IL-2). Several strategies to improve im-
mune reconstitution in HIV patients have been considered
during the last decade. Most of these strategies aim to
increase thymus activity and/or peripheral proliferation.
Of all suggested strategies supplementary treatment with
recombinant human (rh)IL-2 is the best described. Thus,
several studies have shown that combination therapy with
rhIL-2 and HAART increases CD4+ cell counts in HIV
patients compared to HAART alone (reviewed in [168]). The
increased level of CD4+ cells is long-lasting and is caused
by peripheral proliferation, although increased thymopoiesis
m a yc o n t r i b u t ea sw e l l[ 169]. Despite increased CD4+
cell counts, supplementary treatment with rhIL-2 did not
result in clinical beneﬁt for the treated patients, which was
demonstrated in two large randomized prospective clinical
trials (ESPRIT, 4111 patients, and SILCAAT, 1695 patients).
The ESPRIT study revealed an increased risk of grade 4
clinical event in the IL-2-treated group. However, these data
did not illustrate the (adverse) eﬀects of supplementary
rhIL-2 treatment in INR as median CD4+ cell counts were
>400cells/μL in the ESPRIT study, and <200cells/μL in the
SILCAAT study. In fact, stratiﬁed results for patients with a
CD4+ cell count <200cells/μL in the SILCAAT study showed8 Clinical and Developmental Immunology
a nonsigniﬁcant decreased risk of adverse eﬀect in the IL-2
treatment arm and still a signiﬁcant increase in CD4+ cell
count. A small study conﬁrmed increased CD4+ cell count
in INR after supplementary rhIL-2 treatment and demon-
strated enhanced immune function ex vivo [170]. Also, a
higher incidence of HIV-related clinical events has been
observed among INR receiving HAART alone than among
subjects receiving HAART plus IL-2 [171]. In conclusion, at
present supplementary rhIL-2 has no place as a therapeutic
agent in the treatment of HIV infection. However, it cannot
be completely ruled out that INR may beneﬁt, but it must
be considered with great caution, and further studies are
warranted to conclude whether any clinical beneﬁt exists for
supplementary IL-2 treatment in INR.
6.3. IL-7. As described, IL-7 is an essential regulator of
the T-cell homeostasis. Administration of rhIL-7 to HIV-
infected patients is being tested in several ongoing clinical
trials (clincialtrials.gov, reviewed in [172]). Animal studies
[173]a n dp h a s eI / I Is t u d i e sr e p o r tt h a tI L - 7i sw e l lt o l e r a t e d ,
but rhIL-7 administration causes a transient increase of
viral replication [174, 175]. However, concomitant HAART
counteracts this adverse eﬀect and supplementary rhIL-
7t r e a t m e n th a sp r o v e ns a f e[ 174, 175]. Subcutaneous
administration of single dose of rhIL-7 (3–100μg/kg) [174]
as well as intermittent doses (3 or 10μg/kg) [175] results
in signiﬁcant dose-dependent increase in CD4+ cell counts.
This increase includes both central memory cells and naive
cells. Importantly, administration of rhIL-7 has been shown
to increase levels of RTE, numbers of TRECs, as well as
increase naive CD4+ cell counts resulting in a broadening
of immunological repertoire, thus indicating increased thy-
mopoiesis [176–178]. Furthermore, preliminary data from
the INSPIRE 2 study indicate that administration of rhIL-
7 induces expansion of CD4+ cells in the gut mucosa due
to increased expression of homing receptors [179]a sw e l l
as lower expression of PD-1 suggestive of reduced immune
activation. Thus, administration of rhIL-7 as supplementary
treatment shows great promise. However, as lymphopenic
HIV-infected patients present with physiological increased
concentration of IL-7 [54, 55], exogenous IL-7 administra-
tion might be futile. Fortunately, animal studies [173]a n d
phase I/II clinical trials reveal a signiﬁcant increase in CD4+
cell count in individuals with low CD4+ cell counts and high
IL-7 concentrations (reviewed in [172]). This ﬁnding may
be due to the fact that circulating levels of IL-7 after rhIL-
7 administration are much higher than physiological levels.
Data from larger randomized clinical trials are warranted
to determine the potential eﬀect of adding IL-7 to HAART
for immune reconstitution in INR, bearing the result of
supplementary administration of IL-2 in mind.
6.4. IL-15. IL-15 is a cytokine that is structurally comparable
to IL-2 and regulates proliferation and activation of T cells,
and IL-15 has therefore been considered as a potential
therapeutic agent in HIV infection. Treatment with IL-
15 has primarily been investigated in murine and simian
models [180, 181] with conﬂicting results. Combining IL-
15 and HAART has proven to increase CD4+ cell and
CD8+ cell counts in SIV-infected rhesus macaques (RMs)
[182]. However, another study reported no eﬀect of IL-15
administration on CD4+ cell counts but only on CD8+ cell
countsandNKcells[181,183].Furthermore,administration
ofIL-15inacuteSIVinfectionresultedinincreasedviralload
andincreaseddiseaseprogression[183],andsimilarlyadding
IL-15 to HAART in SIV-infected RMs resulted in decreased
CD4+ cell counts. In conclusion, adding IL-15 to HAART is
expected to result in limited beneﬁt for INR.
6.5. Growth Hormone (GH). Studies with supplementary
therapy with GH in patients with HIV infection have orig-
inally been conducted to examine whether GH could be
used a therapeutic agent for HIV-associated wasting and
lipodystrophy (reviewed in [184, 185]). However, treatment
with rhGH supplement to HAART has demonstrated to
increaseCD4+cellcountscomparedtoHAARTaloneinran-
domized, prospective clinical trials [186–190], and further
clinical trials are ongoing (http://www.clinicaltrials.gov/).
Furthermore, the supplementary rhGH given subcutaneous
in doses from 0.7 to 3mg/day resulted in an increase in
thymic size in alignment with an increase in RTE, TREC
number, and naive CD4+ cells [186–190], indicating an
increased thymopoiesis. The patients included in these
studies had median CD4+ cell counts <400cells/μL[ 187,
190] and 350cells/μL[ 186], respectively, and may therefore
include a group of INR. However, adverse eﬀects such as
carpal tunnel syndrome, arthralgia, glucose intolerance, or
cancer progression were frequent and result in a limited
use of rhGH as a therapeutic agent. A potential strategy to
reduce adverse eﬀectisbyusingGHreleasingfactor(GHRF),
which seems to cause fewer adverse eﬀects (reviewed in
[191, 192]). However, so far the eﬀects of treatment with
GHRF have primarily been addressed to lipodystrophia
[192], (http://www.clinicaltrials.gov/), and indeed clinical
trials testing the eﬀect of GHRF on immune reconstitution
are warranted.
6.6. Keratinocyte Growth Factor (KGF). KGF causes prolifer-
ation and diﬀerentiation in thymic epithelial cells, and KGF
pretreatment in mice and in rhesus macaques after myeloab-
lative irradiation has proven to enhance thymopoiesis and
increase thymic output [193–195]. However, a phase I/II
randomized placebo-controlled study, originally designed to
assess the eﬀect of 40–60μg/kg KGF per day on graft versus
host disease (GVHD) in 100 patients undergoing allogenic
hematopoietic stem cell transplantation, showed no eﬀect
o fK G Fo na b s o l u t el y m p h o c y t ec o u n t[ 196, 197]. Thus,
the addition of KGF to enhance immune reconstitution in
INR on HAART is theoretically plausible, and results are
awaited from a randomized phase II study testing the eﬀect
of palifermin (recombinant human KGF) injection at doses
from 20 to 60μg/kg per day in HIV patients on HAART with
CD4 count <250 cells/μL( http://www.clinicaltrials.gov/).
6.7. Immune Suppression. The impact of immune activation
isdescribedpreviously.SeveralstrategieshavebeensuggestedClinical and Developmental Immunology 9
to reduce immune activation. New biological immunomod-
ulators (inhibitors of TNF-alfa, IL-6, IL-1) for autoim-
mune diseases may prove to be therapeutic possibilities to
suppression of immune activation in HIV infection. How-
ever, use of such immunomodulators must be done with
great care taking into account the increased risks of oppor-
tunistic infections. Currently, there is limited experience,
but HIV-infected patients with an autoimmune disease have
been treated with TNF-α inhibitors with acceptable results
for patients with CD4+ cell counts >200cells/μL( r e v i e w e d
in [198, 199]). A small study described reduced immune
activation and increased CD4+ cell count in treatment na¨ ıve
patientsafterintravenousimmunoglobulin(IVIG)(0.4g/kg)
[200]. However, this was not conﬁrmed in another small
study reporting no eﬀect of high dosage IVIG (30 gram for
ﬁve days) in treatment-experienced patients [201, 202], but
interestingly IVIG administration resulted in a reduction of
HIV reservoirs in CD4+ cell counts after treatment which
may be a contributor to the failure of immune recovery
in INR. Chronic coinfection with other infectious agents is
a potential cause of increased immune activation in HIV-
infected patients. Decreased immune activation has been
documented after therapeutic clearance of HCV infection
with interferon-α and ribavirin [203] .L i k e w i s e ,ar a n d o m -
ized clinical trial including 30 HIV-infected patients with
CMVcoinfectiondocumentedadecreaseinchronicimmune
activation after CMV treatment in HIV patients with CD4+
cell counts <350cells/μL[ 204]. However, no diﬀerence in
CD4+ cell count and HIV load was found.
6.8. Microbial Translocation. Microbial translocation has
been suggested as a cause of immune activation and CD4+
cell depletion in HIV-infected patients [205–207]. High lev-
els of 16S rDNA during therapy have been shown to be asso-
ciated with reduced increases in the CD4+ cell counts [208],
and heightened circulating lipopolysaccharide be associated
with plasma enterobacterial DNA [209]. Thus, microbial
translocation may be a potential target to decrease immune
activation.Probioticshavebeentestedinrandomizedclinical
trial in HIV-infected patient with CD4+ cell counts above
200cells/μL; however the results were disappointing [210].
Furthermore, the eﬀects of hyperimmune bovine colostrums
on CD4+ cell counts in INR were tested in a randomized
clinical trials including 75 patients [163]. No change in
immune activation or CD4+ cell counts was found. Thus,
strategies to improve immune reconstitution in INR by
modulation of microbial translocation are yet to emerge.
6.9. Cox-2 Inhibitor. Finally, another approach suggested to
reduce immune activation is cyclooxygenase type 2 (Cox-
2) inhibitors which have been tested in clinical trials with
promising results. Treatment with Cox-2 inhibitors clearly
decreases immune activation in HIV-infected patients [211–
213], and combination treatment with HAART and Cox-
2 inhibitor resulted in increased CD4+ cell counts [212,
213]. These studies were conducted in HIV-infected patients
with median CD4+ cell counts >400cells/μL, and larger
clinical trials assessing the eﬀect of Cox-2 inhibitors in INR
are needed to uncover a potential for optimizing immune
recovery.
7. Conclusion andFutureDirections
Following the introduction of HAART, the prognosis and life
expectancy for HIV-infected patients has changed tremen-
dously. Thus, patients with optimal immune reconstitution
and lack of comorbidity have a life expectancy almost
comparable to HIV negative individuals. However, rates of
morbidity and mortality including both AIDS- and non-
AIDS-related events increase substantially with persistent
low CD4+ cell counts. Therefore, increased morbidity and
mortality persist in patients who do not achieve full immune
reconstitution, in particular in INR.
INRs have immunological dysfunctions in both pro-
duction and destruction of CD4+ cells. A well-functioning
bone marrow, a large thymus with adequate function, and
a high output of na¨ ıve cells are all critical components for
production of CD4+ cells and immune reconstitution. It is
plausible that dysfunctions in one or more of these param-
eters contribute to the low CD4+ cell counts in INR. Also,
INRs have higher levels of immune activation and apoptotic
cells indicating a higher loss of CD4+ cells. With the known
signiﬁcant impact of immune activation on the prognosis
in HIV-infected individuals, it is reasonable to conclude
that a high level of immune activation is a contributing
factor to poor immune reconstitution as well. Furthermore,
a dysregulated balance between pro- and anti-inﬂammatory
T cells in INR may have an inﬂuence on immune reconsti-
tution, but deﬁnitive documentation is lacking. Finally, it is
likely that disruptions in the secondary lymphatic tissue may
contribute to lack of immune reconstitution. However, with
the present level of knowledge, it is diﬃcult to determine
whether these immunological disturbances are reﬂecting
a poor immunological reconstitution rather than causing
them. Only well-designed large prospective studies can help
clarify this.
So far, a range of supplementary treatment to HAART
has been suggested to improve immune reconstitution.
The only thoroughly investigated candidate has been IL-2
that unfortunately proved not to be beneﬁcial for clinical
outcome. Several candidates seem promising including sup-
plementary treatment with IL-7, GH releasing analogues,
and possibly Cox-2 inhibitors. Furthermore, using Mar-
aviroc as an integrated component of HAART does seem
to result in higher CD4+ cell counts, but at present, the
possibilities of improving the immune reconstitution in INR
using supplementary treatment are limited. Some predictive
factors can be avoided. Early diagnosis could be improved,
reducing the risk for a low CD4 nadir, and coinfection
with hepatitis C can be treated. However, understanding and
improving immune reconstitution in HIV-infected patients
remains an important ﬁeld of research.
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